Viral infections are a major and continuing global healthcare threat. Respiratory viral infections have reached epidemic and pandemic magnitude – and there is clear need for novel enhanced antiviral agents.
Deadly viral diseases such as influenza, HIV, AIDS, Zika virus, dengue and SARS-CoV-2 have emerged and their spread globally has become faster and more dangerous.
In the fight against these viruses, there is a clearly understood need for effective antiviral therapeutics in addition to vaccines.
ILC Therapeutics is a UK-based biotechnology company and pioneer in the discovery and development of a ground-breaking new class of interferon drugs.
ILC Therapeutics Ltd.
BioCity,
Bo’ness Road, Newhouse,
Lanarkshire, Scotland, UK,
ML1 5UH